{
  "docId": "019de076-f846-767d-9b7f-8682a04c3e89",
  "docSlug": "d28195e1bb64bc51ad898953c5c30263",
  "documentTitle": "Boundless Bio | IPO Presentation Deck | 51 slides",
  "authorId": "boundless-bio",
  "authorName": "Boundless Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 4,
  "pageCount": 51,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes a 'Fierce Biotech Fierce 15' award badge.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f846-767d-9b7f-8682a04c3e89/4",
  "deckHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89",
  "deckJsonHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89.json",
  "deckAnchorHref": "/decks/019de076-f846-767d-9b7f-8682a04c3e89#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.17,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": "Fierce Biotech Fierce 15 award badge",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71193e90-46de-42d6-84e0-66a1911779a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.25,
        "y": 0.78
      },
      "kind": "list",
      "text": "Experienced team: Track record of drug/diagnostic approvals, multi-$B M&A; >$250M raised from blue-chip investors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17bf61a6-28b3-4f0b-88c6-72d41e3ff4fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.25,
        "y": 0.38
      },
      "kind": "list",
      "text": "ecDNA: Cancer-specific circular DNA; Transformative emerging area; Spyglass drug discovery platform",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26777210-ec2e-427d-921e-0a7d9094423c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.25,
        "y": 0.56
      },
      "kind": "list",
      "text": "ecDNA-directed therapies (ecDTx): BBI-355 (Phase 1/2 2H 2024), BBI-825 (Phase 1/2 2H 2025), ecDTx 3, ECHO diagnostic",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35ff5886-9093-4e8a-998b-4a012a0675c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "list",
      "text": "Oncogene amplified cancer: Generally unresponsive to targeted therapy and immunotherapy; Significant unmet medical need; ~1.3M new patients per year",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2e1b43e-d4ae-4c09-8f20-7275f7cd5c05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. United States, EU, and Japan; ecDTx: ecDNA-directed therapy; ECHO: ecDNA Harboring Oncogenes; BBI's proprietary ecDNA diagnostic",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33087238-d449-43cd-84e6-71d2a57d7f1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Boundless Bio: clinical-stage company establishing a new category in oncology that addresses oncogene amplified cancers via targeting extrachromosomal DNA (ecDNA)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05aa403d-2f10-4c96-9e89-2a27e857fbe7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}